Target Name: VWA2
NCBI ID: G340706
Other Name(s): von Willebrand factor A domain-containing protein 2 | A-domain containing protein similar to matrilin and collagen | Colon cancer diagnostic marker | Von willebrand factor A domain-containing 2 | Colon cancer secreted protein 2 | VWA2_HUMAN | colon cancer diagnostic marker | colon cancer secreted protein 2 | NET42 | AMACO | Colon cancer secreted protein-2 | CCSP2 | OTTHUMP00000043931 | Von Willebrand factor A domain containing 2 | Von Willebrand factor A domain-containing protein 2 | VWA2 variant 1 | A domain-containing protein similar to matrilin and collagen | von Willebrand factor A domain containing 2 | CCSP-2 | a domain-containing protein similar to matrilin and collagen | MGC157755 | Von Willebrand factor A domain containing 2, transcript variant 1

VWA2: A Protein Involved in Blood Clots

VWA2, or von Willebrand factor A domain-containing protein 2, is a protein that is expressed in most tissues of the body. It is a member of the A subunit of the von Willebrand factor complex, which is a protein that plays a role in blood clotting. VWA2 is composed of 254 amino acids and has a calculated molecular weight of 31.1 kDa.

The von Willebrand factor complex is a protein that is composed of four subunits: A, B, C, and D. The A subunit is the most abundant and is responsible for the formation of platelet aggregates, which are the clusters of cells that form when a blood clot forms. The B subunit is responsible for the aggregation of red blood cells, the C subunit is responsible for the aggregation of white blood cells, and the D subunit is responsible for the aggregation of platelet cells.

VWA2 is a protein that is expressed in most tissues of the body and is involved in the formation of blood clots. It is a key player in the von Willebrand factor complex and is involved in the aggregation of platelet cells. This protein is thought to be a potential drug target or biomarker and is the focus of research in the field of haemostasis, which is the study of blood clotting and blood pressure.

The von Willebrand factor complex plays a vital role in the formation of blood clots. When a blood clot forms, platelet cells aggregate around the clot and forms a plug to prevent the clot from spreading. The A subunit of the von Willebrand factor complex is responsible for the formation of the platelet aggregates.

VWA2 is a key protein in the von Willebrand factor complex and is involved in the aggregation of platelet cells. It is thought to be a potential drug target or biomarker and is the focus of research in the field of haemostasis.

Research into VWA2 has identified several potential drug targets. One of the main targets is the A subunit of the von Willebrand factor complex, which is responsible for the formation of platelet aggregates. Researchers are interested in developing drugs that can inhibit the activity of this subunit and prevent blood clots from forming.

Another potential target for VWA2 is the C subunit of the von Willebrand factor complex, which is responsible for the aggregation of white blood cells. Researchers are interested in developing drugs that can inhibit the activity of this subunit and prevent the formation of white blood cells aggregations.

In addition to its potential drug targets, VWA2 is also being studied as a biomarker for the diagnosis and assessment of blood clotting disorders. The von Willebrand factor complex is a key player in the formation of blood clots and researchers are interested in using VWA2 as a biomarker to monitor the effectiveness of treatments for blood clotting disorders.

Conclusion

VWA2 is a protein that is involved in the formation of blood clots and is a key player in the von Willebrand factor complex. It is thought to be a potential drug target or biomarker and is the focus of research in the field of haemostasis. Further studies are needed to fully understand the role of VWA2 in the formation of blood clots and to develop effective treatments for blood clotting disorders.

Protein Name: Von Willebrand Factor A Domain Containing 2

More Common Targets

VWA3A | VWA3B | VWA5A | VWA5B1 | VWA5B2 | VWA7 | VWA8 | VWC2 | VWC2L | VWCE | VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7